Clinical trials: Monoclonal Antibody
Multiple Myeloma
Selinexor Treatment of Refractory Myeloma
This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with penta-refractory MM (Parts 1 and 2) or quad refractory MM…
- Trial name
- STORM (NCT02336815)
- Testing
- Selinexor, Dexamethasone
- Where
- 61 sites in United States, Austria and 4 more
- Volunteers
- 202 people
- Sponsor
- Karyopharm Therapeutics Inc
Metastatic Colorectal Cancer
Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
This is a single arm, phase 2, open-label, multicenter trial in patients with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) and documented…
- Trial name
- NCT02965417
- Testing
- Sym004
- Sponsor
- Symphogen A/S
Multiple Sclerosis
A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis
The purpose of the study is to evaluate the effectiveness and safety of CNTO 1275 in patients with Multiple Sclerosis
- Trial name
- NCT00207727
- Testing
- CNTO 1275
- Volunteers
- 249 people
- Sponsor
- Centocor, Inc.
Metastatic Colorectal Cancer
Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR Monoclonal antibody（SCT200）in patients with wild-type RAS and BRAF mCRC treated with fluorouracil, oxaliplatin and irinotecan after failure…
- Trial name
- NCT03405272
- Testing
- Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
- Where
- 21 sites in China
- Volunteers
- 110 people
- Sponsor
- Sinocelltech Ltd.
Healthy
A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects
To evaluate the safety and tolerability of raxibacumab in healthy subjects.
- Trial name
- NCT00639678
- Testing
- raxibacumab
- Volunteers
- 322 people, healthy volunteers welcome
- Sponsor
- Human Genome Sciences Inc.
Primary Sjögren Syndrome
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with primary Sjögren's syndrome.
- Trial name
- NCT07375524
- Testing
- ESG206
- Where
- 21 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd
Asthma
A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma
This study will assess the effcacy and safety of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.
- Trial name
- NCT06680947
- Testing
- 610
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Non-squamous Non-small-cell Lung Cancer
A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer
This trial is a randomized, double-blind, parallel-controlled, multicenter phase III clinical study. To evaluate the clinical efficacy of SIBP04 in patients with locally advanced, metastatic or recurrent non-squamous non-small…
- Trial name
- NCT05318443
- Testing
- SIBP04, Avastin, Paclitaxel
- Where
- China
- Volunteers
- 512 people
- Sponsor
- Shanghai Institute Of Biological Products
End-Stage Renal Disease, End-Stage Kidney Disease
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD) participants receiving hemodialysis via an…
- Conditions
- End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
- Trial name
- NCT05027074
- Testing
- MK-2060
- Where
- 120 sites in United States, Argentina and 13 more
- Volunteers
- 506 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Participants
An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab
The purpose of this study is to compare the pharmacokinetic (PK) exposures of a single subcutaneous (SC) dose of tozorakimab administered using AI or APFS in healthy participants.
- Trial name
- NCT06908577
- Testing
- Tozorakimab, Autoinjector (AI) Device, Accessorised Prefilled Syringe (APFS) Device
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Dermatitis, Atopic
A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis
The purpose of this research study is to investigate if KY1005 results in improvement of eczema when given to participants with moderate to severe disease. Side effects of KY1005 will also be explored.
- Trial name
- NCT03754309
- Testing
- KY1005
- Where
- 19 sites in Germany, Poland and 2 more
- Volunteers
- 89 people
- Sponsor
- Kymab Limited
Multiple Myeloma
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma.
- Trial name
- NCT05137054
- Testing
- Linvoseltamab, Daratumumab, Carfilzomib
- Where
- 42 sites in United States, France and 3 more
- Volunteers
- 317 people
- Sponsor
- Regeneron Pharmaceuticals
Melanoma
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
The purpose of this study is to investigate the pharmacokinetics (PK) similarity of Bmab1700 (an intended nivolumab biosimilar), compared with United States (US)-licensed Opdivo, in participants after complete surgical removal of…
- Trial name
- NCT07476326
- Testing
- Bmab1700, Opdivo
- Where
- 46 sites in Brazil, Chile and 8 more
- Volunteers
- 120 people
- Sponsor
- Biocon Biologics UK PLC
Alzheimer's Disease
Effect of LY2062430 on the Progression of Alzheimer's Disease
Alzheimer's disease (AD) is an age-related degenerative disorder of the brain, characterized by progressive decline in cognitive function and ability to perform activities of daily living, and ultimately can lead to death due to…
- Trial name
- EXPEDITION (NCT00905372)
- Testing
- LY2062430
- Where
- 85 sites in United States, Argentina and 3 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Hepatocellular
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
The primary purpose of the study is to explore whether treatment with PF-03446962 and best supportive care is better than placebo plus best supportive care in prolonging survival of patients affected by recurrent liver cancer.
- Trial name
- NCT01911273
- Testing
- PF-03446962, Best Supportive Care
- Where
- 4 sites in United States, Japan
- Volunteers
- 3 people
- Sponsor
- Pfizer
Burkitt Lymphoma, Precursor B-cell Lymphoblastic Leukemia-Lymphoma
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL)…
- Trial name
- NCT01786096
- Testing
- SGN-CD19A
- Where
- 13 sites in United States
- Volunteers
- 92 people
- Sponsor
- Seagen Inc.
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Rheumatoid Arthritis
A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)
The purpose of this study is to evaluate the safety and effectiveness of golimumab in patients with active rheumatoid arthritis despite DMARD (Disease-modifying antirheumatic drugs) therapy.
- Trial name
- NCT00771251
- Testing
- CNTO 148
- Where
- 67 sites in Japan
- Volunteers
- 311 people
- Sponsor
- Janssen Pharmaceutical K.K.
ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis
The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab
The goal of this clinical trial is to learn whether a nasal spray medicine called foralumab is safe and easy to tolerate in adults with amyotrophic lateral sclerosis (ALS).
- Conditions
- ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS
- Trial name
- BANYAN (NCT07688239)
- Testing
- Foralumab Nasal
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Tiziana Life Sciences LTD
Atopic Dermatitis
Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study for subjects with moderate to severe AD whose disease cannot be adequately controlled with topical medications or for whom topical…
- Trial name
- NCT03703102
- Testing
- KHK4083
- Where
- 58 sites in United States, Canada and 2 more
- Volunteers
- 274 people
- Sponsor
- Kyowa Kirin, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.